

## Supplemental Online Content

Kawatkar AA, Sharp AL, Baecker A, Natsui S, Redberg RF, Lee M-S, Ferencik M, et al. Early Noninvasive Cardiac Testing After Emergency Department Evaluation for Suspected Acute Coronary Syndrome. *JAMA Intern Med*. Published online October 5, 2020. doi:10.1001/jamainternmed.2020.4325

**eTable 1.** Logistic Regression of First Stage IV Model Predicting Early NIT

**eTable 2.** Overall Diagnostic Test for the IV Model Assumptions

This supplemental material has been provided by the authors to give readers additional information about their work.

**eTable 1. Logistic Regression of First Stage IV Model Predicting Early NIT**

|  | <b>Odds Ratio</b> | <b>Lower 95% CI</b> | <b>Upper 95% CI</b> |
|--|-------------------|---------------------|---------------------|
| Medical Center Practice Pattern  | <b>1·06</b>       | <b>1·06</b>         | <b>1·07</b>         |
| Day of the Week IV   |                   |                     |                     |
| Weekday  | Reference         |                     |                     |
| Weekend  | <b>0·82</b>       | <b>0·78</b>         | <b>0·88</b>         |
| Age Categories   |                   |                     |                     |
| 18-49  | Reference         |                     |                     |
| 50-69  | <b>3·0</b>        | <b>2·84</b>         | <b>3·16</b>         |
| 70 and Above   | <b>3·34</b>       | <b>3·12</b>         | <b>3·56</b>         |
| Sex  |                   |                     |                     |
| Female   | Reference         |                     |                     |
| Male   | <b>1·19</b>       | <b>1·15</b>         | <b>1·24</b>         |
| Race Categories  |                   |                     |                     |
| White  | Reference         |                     |                     |
| Black  | <b>0·90</b>       | <b>0·85</b>         | <b>0·95</b>         |
| Asian  | <b>1·66</b>       | <b>1·0003</b>       | <b>1·13</b>         |
| All Other Race   | 0·96              | 0·91                | 1·005               |
| Smoking Status   |                   |                     |                     |
| Never Smoked   | Reference         |                     |                     |
| Quit Smoking   | 0·98              | 0·94                | 1·02                |
| Active/Passive Smoker  | 1·02              | 0·95                | 1·10                |
| Body Mass Index (BMI)  |                   |                     |                     |
| Normal BMI   | Reference         |                     |                     |
| Under Weight   | <b>0·76</b>       | <b>0·62</b>         | <b>0·93</b>         |
| Overweight   | <b>1·15</b>       | <b>1·10</b>         | <b>1·20</b>         |
| Obese  | <b>1·30</b>       | <b>1·23</b>         | <b>1·36</b>         |
| Elevated Troponin (0·04-0·5)   | <b>1·37</b>       | <b>1·25</b>         | <b>1·50</b>         |
| Coronary Artery Disease (CAD)  | <b>0·84</b>       | <b>0·80</b>         | <b>0·89</b>         |
| Stroke   | 0·93              | 0·83                | 1·05                |
| Percutaneous transluminal coronary angioplasty (PTCA) or Coronary artery bypass graft (CABG) in prior year | <b>0·64</b>       | <b>0·53</b>         | <b>0·77</b>         |
| Family history of CAD  | <b>1·13</b>       | <b>1·08</b>         | <b>1·17</b>         |

|  |             |             |             |
|--|-------------|-------------|-------------|
| Family history of Stroke   | 0·98        | 0·93        | 1·03        |
|  |             |             |             |
| Antidiabetic medications<br>in past 90 days  | <b>1·24</b> | <b>1·17</b> | <b>1·31</b> |
| Anticoagulant medications<br>in past 90 days   | <b>0·89</b> | <b>0·84</b> | <b>0·95</b> |
| Anti-hyperlipidemic medications<br>in past 90 days   | <b>1·13</b> | <b>1·08</b> | <b>1·18</b> |
| Anti- hypertension medications<br>in past 90 days  | <b>1·17</b> | <b>1·12</b> | <b>1·23</b> |
|  |             |             |             |
| Elixhauser Comorbidity Index   | <b>0·93</b> | <b>0·92</b> | <b>0·94</b> |
| <p><b>Bold Font</b> Indicates Statistically Significant Estimates<br/> <i>Logit model estimates are only presented for ease of interpretability of the odds ratio. Actual estimation used a probit model specification instead of logit model.</i></p> |             |             |             |

**eTable 2. Overall Diagnostic Test for the IV Model Assumptions**

| Model Assumption   | Diagnostic test type                   | Death/Acute MI<br>Test statistic<br>( <i>P</i> value) or Stock-Yogo (2005) Critical Value* | Death<br>Test statistic<br>( <i>P</i> value) or Stock-Yogo (2005) Critical Value* | Acute MI<br>Test statistic<br>( <i>P</i> value) or Stock-Yogo (2005) Critical Value* | Coronary Revascularization<br>Test statistic<br>( <i>P</i> value) or Stock-Yogo (2005) Critical Value* | MACE<br>Test statistic<br>( <i>P</i> value) or Stock-Yogo (2005) Critical Value* |
|--|--|--|---|--|--|--|
| Instrument Strength  | First Stage F                          | 1531<br>( <i>p</i> <0.0001)  | 1531<br>( <i>p</i> <0.0001)   | 1531<br>( <i>p</i> <0.0001)  | 1531<br>( <i>p</i> <0.0001)  | 1531<br>( <i>p</i> <0.0001)  |
| Weak Instrument  | Cragg-Donald Wald F statistic          | 1475<br>(8.7)*   | 1475<br>(8.7)*  | 1475<br>(8.7)*   | 1475<br>(8.7)*   | 1475<br>(8.7)*   |
| Rank Test/Under-identification test  | Kleibergen-Paap rk LM statistic        | 2816<br>( <i>p</i> <0.0001)  | 2816<br>( <i>p</i> <0.0001)   | 2816<br>( <i>p</i> <0.0001)  | 2816<br>( <i>p</i> <0.0001)  | 2816<br>( <i>p</i> <0.0001)  |
| Overidentification   | Sargan-Hansen test <i>J</i> -statistic | 0.902<br>( <i>p</i> =0.34)   | 0.144<br>( <i>p</i> =0.70)  | 0.42<br>( <i>p</i> =0.52)  | 0.05<br>( <i>p</i> =0.82)  | 0.76<br>( <i>p</i> =0.38)  |
| Instrument redundancy  | LM test of redundancy                  | 2747<br>( <i>p</i> <0.0001)  | 2747<br>( <i>p</i> <0.0001)   | 2747<br>( <i>p</i> <0.0001)  | 2747<br>( <i>p</i> <0.0001)  | 2747<br>( <i>p</i> <0.0001)  |
| <i>Testing is based on linear additive specification. Actual estimation used a probit model for the treatment choice (early NIT vs not) as well as probit model for the binary outcomes associated with death, acute myocardial infarction, coronary revascularization and major adverse cardiovascular events</i> |  |  |   |  |  |  |

The order condition for identification of an IV model is a necessary condition and generally easy to check. The order condition however is not a sufficient condition. To ensure that the necessary and sufficient rank condition was satisfied, we checked the Kleibergen-Paap Lagrange multiplier (LM) statistic.<sup>1,2</sup> The precision of IVs parameters is generally lower and in the presence of weak instruments, the loss of precision will be severe.<sup>2,3</sup> The problem with weak instruments arises when the strength of the correlation between the endogenous regressors and the excluded instruments is statistically significant but small in magnitude.<sup>4,5</sup> We evaluated the validity of our IV approach to the weak instruments problem on the basis of the individual first-stage F-statistic and also the Angrist-Pischke first-stage F-statistic.<sup>6</sup>

To check if the excluded instruments are uncorrelated to the error we performed overidentification test. This orthogonality condition is generally not confirmed statistically. However, in the overidentified case, if we maintain the hypothesis that the model is identified, a rejection of the hypothesis implies rejecting the orthogonality conditions. Given these assumptions, an overidentification test was performed for all excluded instruments on the basis of the Hansen J-statistic to ensure that the excluded instruments are uncorrelated to the error.<sup>2,3,7-9</sup> Lastly, because our model was overidentified, it is important to ensure that the excluded instruments are not redundant and that each adds to the efficiency of the estimator. On the basis of the LM test, we checked the redundancy of the IV medical center practice pattern conditional on the weekend IV as the excluded instrument.<sup>10-12</sup> Most of the test statistics were made robust to arbitrary heteroskedasticity.<sup>13</sup>

The IV specification testing presented in supplemental table 2 indicated that the two excluded instruments: 1. Medical Center Practice Pattern and 2. Day of the Week were a) strongly correlated to the treatment (i.e. NIT within 3 days); b) were not weak instruments; c) satisfy the order as well as rank condition; d) were not redundant and lastly were orthogonal to the outcome error and appropriately excluded from the outcome model since they only acted through the exposure of early NIT. The IV models satisfied all assumption necessary for consistent estimate of the parameters.

The average treatment effect parameter identified by our IV models maybe sensitive to our covariate or functional form specification.<sup>6</sup> Additionally, it could be the case that medical centers with higher NIT preference may have increased adoption of other ACC/AHA guidelines and/or protocols that may improve outcomes. To mitigate these concerns, we estimated the local average treatment effect (LATE) as the ratio of the expected death/MI risk reduction to the probit model estimate of day of the week IV.<sup>6</sup> This LATE estimate was a 3.7% reduction in risk of the primary outcome. Though LATE is based on weaker assumption compared to the IV models, it only applies to compliers i.e. those patients who are influenced to undertake treatment only by change in value of the IV and not otherwise.<sup>14</sup> Some non-compliers could be unusually sick and/or maybe persistent in obtaining NIT even on weekends or at medical centers with low preferences due to being unusually organized and aware. Non-compliers also include a portion that could really benefit from NIT and are strongly advised to have these tests performed, yet they leave without testing, against medical advice. LATE filters out some of these non-compliers and hence it's estimate is higher compared to the estimated average treatment effect.

## REFERENCES

1. Kleibergen F, Paap R. Generalized Reduced Rank Tests Using the Singular Value Decomposition. *Journal of Econometrics*. July 2006 2006;133(1):97-126.
2. Baum C, Schaffer M, Stillman S. Enhanced routines for instrumental variables/GMM estimation and testing. Boston: Boston College 2007.
3. Baum C, Schaffer M, Stillman S. Instrumental variables and GMM: Estimation and testing. *Stata Journal*. March 2003 2003;3(1):1-31.
4. Bound J, Jaeger A, Baker R. Problems with Instrumental Variables Estimation When the Correlation Between the Instruments and the Endogenous Explanatory Variable is Weak. *Journal of the American Statistical Association*. June 1995 1995;90(430):443-450.
5. Staiger D, Stock J. Instrumental variables regression with weak instruments. *Econometrica*. 1997;65(3):557-586.
6. Angrist J, Pischke J. *Mostly Harmless Econometrics: An Empiricist's Companion*. 1 ed. Princeton Princeton University Press.; 2009.
7. Anderson T. Estimating linear restrictions on regression coefficients for multivariate normal distributions. *Annals of Mathematical Statistics*. 1951;22(3):327-351.
8. Anderson T. *Introduction to Multivariate Statistical Analysis*. 2d ed. . Vol 2d ed. New York: John Wiley & Sons 1984.
9. Anderson T, Rubin H. Estimation of the parameters of a single equation in a complete system of stochastic equations. *Annals of Mathematical Statistics*. March 1949 1949;20(1):46-63.
10. Breusch T, Qian H, Schmidt P, Wyhowski D. Redundancy of moment conditions. . *Journal of Econometrics*. July 1999 1999;9(1):89-111.
11. Hall A, Peixe F. A Consistent Method for the Selection of Relevant Instruments. . *Econometric Reviews*. 2003;25(5):269-287.
12. Hall A, Rudebusch G, Wilcox D. Judging instrument relevance in instrumental variables estimation. *International Economic Review*. 1996;37(2):283-298.
13. *xtivreg2: Stata module to perform extended IV/2SLS, GMM and AC/HAC, LIML and k-class regression for panel data models* [computer program]. Chestnut Hill, MA: Boston College Department of Economics; 2010.
14. Heckman J, Urzua S, Vytlacil E. *Instrumental Variables In Models With Multiple Outcomes: The General Unordered Case*. Dublin: University College Dublin; 2008:38.